Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology

NCT04451837 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of two medications, semaglutide and dapagliflozin, in adults with type 2 diabetes to see how they impact blood sugar levels.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 200 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2020-09 · est. completion 2026-12

Where 1 site · Sweden

What this study is testing ClinicalTrials.gov NCT04451837 ↗

Description as written by the study sponsor.

Current anti-diabetic treatment fails to stop the progressive course of the disease. Recent studies have revealed a surprisingly high variability in the diabetic phenotype. The investigators propose that anti-diabetic treatment should ideally target the underlying pathophysiology of each individual patient. The investigators will therefore test whether the effect of two approved anti-diabetic drugs differs between individuals at different ends of the pathophysiological spectrum: 1) patients with poor insulin secretion, here termed SIDD and 2) patients with high insulin resistance, here termed SIRD. The study may open up a new avenue for more precise treatment of diabetic patients that would be of immediate clinical relevance.

Treatments tested

Semaglutide also known as Ozempic Drug

Ozempic s.c. once weekly for 6 months
Dapagliflozin also known as Forxiga Drug

Forxiga 10 mg p.o. once daily for 6 months

Main thing measured	Hba1c
Sponsor	Region Skane
Conditions studied	Type2 Diabetes
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04451837 ↗